← Back to Home

Fewer Nights Under the Lights: Four-Year Follow-Up of Rare Disease Gene Therapy Finds Two Patients Remain Off Phototherapy

GNT0003 continued to provide varying degrees of benefit to three patients with Crigler–Najjar syndrome four years after treatment, offering clues about durability. However, the experiences of three patients are not enough to establish long-term outcomes and safety in a broader patient population.

By SURL BioNews

For patients with Crigler–Najjar syndrome, nightly exposure to blue light is an important routine for controlling bilirubin and protecting the nervous system. Four-year follow-up of a gene therapy suggests the possibility of changing that routine: of three patients who received the therapeutic dose, two remained off phototherapy, while the third also needed less light exposure.

The follow-up study was published in The New England Journal of Medicine on November 5, 2026. According to information released by trial sponsor Généthon and AFM-Téléthon, all three patients received GNT0003 at Papa Giovanni XXIII Hospital in Bergamo, Italy. Four years later, their bilirubin levels remained below the threshold associated with a risk of neurotoxicity. The central question in this update is whether the early benefits persist over time.

Crigler–Najjar syndrome is an extremely rare congenital liver disease in which patients lack the UGT1A1 enzyme needed to metabolize bilirubin. Bilirubin accumulation can cause irreversible neurological damage and, in severe cases, become life-threatening. Blue-light therapy can help control bilirubin levels; liver transplantation can provide definitive treatment but carries risks of transplant complications. GNT0003 uses an adeno-associated virus serotype 8 (AAV8) vector and aims to restore UGT1A1 expression in the liver to improve bilirubin metabolism.

Alongside the reduced need for phototherapy, the research team observed that alanine aminotransferase (ALT) levels remained normal in all three patients. ALT is a commonly used marker for assessing liver cell injury. The announcement stated that this was a change patients had previously been unable to achieve with phototherapy alone. However, improvement in this marker alone does not mean that all liver functions have returned to normal.

During follow-up, one patient also completed a pregnancy after treatment without complications and gave birth to a healthy baby. This is a case record with meaningful implications for daily life within the long-term follow-up, but a single pregnancy outcome is insufficient to establish the therapy’s general safety for reproduction, pregnancy, or offspring.

This report builds on the phase 1/2 CureCN trial published in 2023. According to Généthon and AFM-Téléthon, the trial’s pivotal phase began in January 2023 to confirm efficacy in a larger population and include children aged 10 and older. The report on the same event published by Medical Xpress was provided by AFM-Téléthon, so these public reports primarily reflect the same set of research findings and cannot be considered multiple independent validations.

The persistence of benefits over four years provides more concrete clinical evidence about whether a single gene therapy treatment can reduce the burden of phototherapy over the long term. However, this update covers only three patients who received the therapeutic dose, one of whom still requires phototherapy. The public summary also did not provide complete adverse event data or individual values. Larger trials and continued follow-up are still needed to determine how long efficacy lasts, whether patients of different ages benefit equally, and what less common long-term risks may emerge.

References

  1. Généthon
  2. AFM-Téléthon
  3. Medical Xpress